Role of mast cell-miR-490-5p in irritable bowel syndrome

Hai-Xia Ren1, Fa-Can Zhang1, He-Sheng Luo1

  • 1Hai-Xia Ren, He-Sheng Luo, Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.

Abstract

Insights

Inhibition of microRNA-490-5p (miR-490-5p) in mast cells promotes apoptosis and reduces proliferation. Down-regulation of miR-490-5p increases mRNA levels of mast cell tryptase and PAR-2.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Immunology

Background:

  • Mast cells play a crucial role in allergic inflammation and immune responses.
  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in various cellular processes.
  • The specific role of miR-490-5p in mast cell function and its involvement in signaling pathways like tryptase/PAR-2 remains to be fully elucidated.

Purpose of the Study:

  • To investigate the functional role of miR-490-5p in regulating mast cell proliferation and apoptosis.
  • To determine the impact of miR-490-5p on the mast cell tryptase/PAR-2 signaling pathway.

Main Methods:

  • Construction of a lentivirus expression vector for miR-490-5p inhibition in the p815 mast cell line.
  • Quantitative real-time PCR (qRT-PCR) to measure miR-490-5p expression.
  • CCK-8 assay and flow cytometry to assess mast cell proliferation and apoptosis.
  • qRT-PCR and Western blot to analyze the mRNA and protein levels of tryptase and PAR-2.

Main Results:

  • Inhibition of miR-490-5p significantly promoted apoptosis and inhibited proliferation of p815 mast cells.
  • Down-regulation of miR-490-5p led to a significant increase in the mRNA levels of both tryptase and PAR-2.
  • While protein levels of tryptase and PAR-2 showed a slight increase, the difference was not statistically significant.

Conclusions:

  • miR-490-5p plays a significant role in mast cell proliferation and apoptosis.
  • Down-regulation of miR-490-5p influences the expression of mast cell tryptase and PAR-2, suggesting its involvement in the tryptase/PAR-2 signaling pathway.
  • These findings suggest miR-490-5p may be a potential therapeutic target in conditions involving mast cell dysregulation, such as irritable bowel syndrome.

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
818
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
953